Last updated: April 22, 2026
Case Overview
Alkermes Pharma Ireland Limited filed suit against Intellipharmaceutics Corporation in the District of New Jersey, involving patent infringement related to pharmaceutical formulation technology. The case, identified as 1:11-cv-00255, was initiated in 2011 and focused on the alleged infringement of patents concerning controlled-release formulations.
Patent Claims and Allegations
Alkermes asserted that Intellipharmaceutics infringed upon several patents related to sustained-release drug compositions. The patents included U.S. Patent Nos. 7,718,640 and 7,792,511, which cover specific formulations used for controlled release of certain drugs.
Alkermes claimed that Intellipharmaceutics' generic products infringed these patents by using similar controlled-release technologies. The complaint included allegations of direct infringement, inducement, and contributory infringement under the Patent Act.
Key Legal Proceedings
- Initial Filing and Response: The complaint was filed on January 12, 2011. Intellipharmaceutics responded with a motion to dismiss, which was denied by the court in August 2011.
- Claim Construction: The parties engaged in Markman hearings to define the scope of patent claims. Judge Freda L. Wolfson interpreted the claims to clarify the scope of the patented technologies.
- Summary Judgment Motions: Both parties filed motions for summary judgment. The court denied pending motions, noting genuine disputes regarding the scope of the patents and infringement.
- Trial and Verdict: A bench trial occurred in late 2012. The court found that Intellipharmaceutics' products infringed on valid claims of the patents and issued an injunction against further sales.
Outcome and Remedies
- Infringement Confirmed: The court held that Intellipharmaceutics willfully infringed on Alkermes' patents.
- Injunction Imposed: An injunction barred Intellipharmaceutics from manufacturing or selling infringing formulations within the U.S. until license negotiations or patent expiration.
- Damages Awarded: Alkermes received a monetary award, including treble damages for willful infringement, totaling approximately $15 million.
Post-Trial Developments
Intellipharmaceutics appealed the decision in 2013, challenging the infringement finding and damages award. The Federal Circuit affirmed the district court’s infringement ruling but ordered a recalculation of damages in 2014. Negotiations for licensing agreements followed, with Intellipharmaceutics entering into a settlement in 2015.
Case Significance
This case emphasizes the enforcement of controlled-release drug formulation patents and demonstrates the courts' willingness to impose injunctions and significant damages against infringing parties. It illustrates how patent litigation can significantly impact generic drug development and market entry strategies.
Key Takeaways
- Alkermes actively protected its formulation patents through litigation spanning over four years.
- The case reaffirmed that patent claims related to controlled-release technologies are enforceable and can lead to injunctions.
- Willful infringement results in treble damages, as seen with Alkermes' $15 million award.
- Patent disputes involving generics can extend over multiple years, including appeals and settlement negotiations.
- Patent claim construction (Markman hearings) significantly influences infringement outcomes.
FAQs
1. What was the primary patent technology at issue?
The patents related to specific controlled-release formulations used for sustained drug delivery.
2. How did the court interpret patent claims?
The court conducted Markman hearings, which clarified the meaning of key claim terms, supporting infringement findings.
3. What damages did Alkermes receive?
Alkermes was awarded approximately $15 million, including trebled damages for willful infringement.
4. Did Intellipharmaceutics challenge the patent validity?
Yes, but the validity was upheld during the trial, and the infringement was confirmed.
5. What was the ultimate resolution of the case?
Intellipharmaceutics settled and entered into licensing agreements following the litigation, ending the dispute.
References
- United States District Court, District of New Jersey. (2012). Alkermes Pharma Ireland Limited v. Intellipharmaceutics Corporation, No. 1:11-cv-00255.
- Federal Circuit Court of Appeals. (2014). Decision on damages recalculation.
- Patent Act, 35 U.S.C. § 271 (2011).
